GEN News Highlights

New CHO Cell Lines on the Horizon for Hisun

(Page
1
of
1)

Horizon Discovery is teaming up with Hisun Pharmaceuticals to optimize Horizon’s newly engineered CHO bioproduction cell line for commercial use. Hisun will be using Horizon’s glutamine synthetase (GS) double knockout cell line for use in therapeutic antibody manufacturing.

GS is a critical enzyme in the metabolism of the amino acid L-glutamine, which is often used as a selection marker in the production of recombinant proteins. GS-negative CHO cell lines, Horizon and Hisun say, work well for stringent selection of high-producing lines and accelerating the development of cell lines within the bioproduction industry, offering advantages over traditional methods that use an expensive and toxic chemical inhibitor of GS.

Horizon, which engineered the CHO cell line using its GENESIS™ gene editing technology, claims that the precision afforded by GENESIS results in an optimal final genotype, with complete control over the desired genomic alterations and with no unwanted off-target effects.

“Horizon’s gene engineering technology is unique in the level of precision it can deliver, and therefore offers great advantages in quality and efficiency for industrial cell-line engineering,” Haibin Wang, svp of Hisun Pharmaceuticals, said.

“ Cell-line development has yet to match the gains made in media and feed technology development,” added Brian Burke, Ph.D., business development manager at Horizon. “Precision gene editing will be a key driver for cell line development, and by selective partnering with leaders like Hisun, Horizon intends to accelerate this process.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.